Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHA-PPQ vs Chloroquine for Vivax Malaria in Vietnam
NCT01887821Phase 4Completed
- Sponsor
- Oxford University Clinical Research Unit
- Start
- Feb 2013
- Primary completion
- Jun 2015
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dihydroartemisinin + piperaquine in Plasmodium vivax malaria (2 arms), sponsored by Oxford University Clinical Research Unit. Primary endpoint: Proportion of patients with adequate response to treatment at Day 63. Started Feb 2013; status: completed.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT01887821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887821.